Renaissance Technologies’s Greenwich LifeSciences GLSI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-38,400
Closed -$382K 3423
2025
Q3
$382K Buy
38,400
+11,100
+41% +$125K ﹤0.01% 2902
2025
Q2
$248K Buy
27,300
+14,800
+118% +$141K ﹤0.01% 3100
2025
Q1
$119K Sell
12,500
-10,200
-45% -$124K ﹤0.01% 3166
2024
Q4
$255K Sell
22,700
-9,800
-30% -$131K ﹤0.01% 3089
2024
Q3
$467K Sell
32,500
-4,400
-12% -$65.2K ﹤0.01% 2823
2024
Q2
$637K Sell
36,900
-600
-2% -$8.77K ﹤0.01% 2580
2024
Q1
$748K Buy
37,500
+900
+2% +$11.1K ﹤0.01% 2665
2023
Q4
$385K Sell
36,600
-17,698
-33% -$177K ﹤0.01% 2882
2023
Q3
$480K Sell
54,298
-24,902
-31% -$234K ﹤0.01% 2719
2023
Q2
$764K Buy
79,200
+28,400
+56% +$318K ﹤0.01% 2636
2023
Q1
$701K Buy
50,800
+17,500
+53% +$278K ﹤0.01% 2694
2022
Q4
$506K Sell
33,300
-23,401
-41% -$268K ﹤0.01% 2942
2022
Q3
$516K Sell
56,701
-48,458
-46% -$448K ﹤0.01% 2917
2022
Q2
$891K Buy
+105,159
New +$1.21M ﹤0.01% 2788
2022
Q1
Sell
-30,000
Closed -$730K 4206
2021
Q4
$730K Buy
+30,000
New +$1M ﹤0.01% 2883

Other funds holding GLSI

Renaissance Technologies's GLSI Position: Q4 2025 in Review

Renaissance Technologies sold out of Greenwich LifeSciences (GLSI) in Q4 2025, closing a stake of 38,400 shares — an estimated $382K sold.

Renaissance Technologies first reported a position in GLSI in Q4 2021 and held it in 15 quarters. The position peaked at $891K in Q2 2022. 50 funds tracked by Wall St. Rank hold GLSI as of Q4 2025.

  • Renaissance Technologies reported no remaining Greenwich LifeSciences position as of Q4 2025 after selling out during the quarter.
  • Renaissance Technologies sold 38,400 Greenwich LifeSciences shares in Q4 2025, an estimated $382K.
  • Renaissance Technologies first reported a position in Greenwich LifeSciences in Q4 2021 and held it in 15 quarters.
  • Renaissance Technologies's Greenwich LifeSciences position peaked at $891K in Q2 2022.
  • 50 funds tracked by Wall St. Rank held Greenwich LifeSciences as of Q4 2025.

Based on Renaissance Technologies's 13F filing for Q4 2025, filed 12 Feb 2026.